ライフサイエンスコーパス: aminonucleoside

1 ty to glomerular damage induced by puromycin aminonucleoside.

2 nduced in rats by the injection of puromycin aminonucleoside.

3 bstitution with dimethylamine gave puromycin aminonucleoside [9-(3-amino-3-deoxy-beta-D-ribofuranosyl

4 oheximide, emetine, puromycin, and puromycin aminonucleoside, a negative analog, were evaluated for t

5 t of differentiated podocytes with puromycin aminonucleoside, an agent that causes foot process effac

6 einuria and hypoalbuminemia in the puromycin aminonucleoside and adriamycin rat models of nephrotic s

7 y was induced in C57BL/6 mice with puromycin aminonucleoside, and the selective A(2A)R agonist ATL313

8 These results demonstrate the effects of 3'-aminonucleoside anomeric configuration on sugar puckerin

9 2'-aminonucleosides are commonly used as sites of post-synt

10 The alpha-3'-aminonucleoside building blocks used for oligonucleotide

11 lar injury, because treatment with puromycin aminonucleoside enhanced proteinuria in TG mice compared

12 ith improved plasma albumin in the puromycin aminonucleoside glomerular disease model.

13 rular proteinuria was induced with puromycin aminonucleoside in rats.

14 awley rats by an i.v. injection of puromycin aminonucleoside in saline; seven control rats received s

15 on of OX-7 monoclonal antibody and puromycin aminonucleoside in which 10(7) SPIO- and DiI-labeled MSC

16 efore or after sublethal injury by puromycin aminonucleoside, in the presence or absence of angiotens

17 athepsin L are protected from cell puromycin aminonucleoside-induced cell detachment.

18 nderscored by the observation that puromycin aminonucleoside-induced cell migration was slowed down i

19 roved podocyte function in the rat puromycin aminonucleoside-induced glomerular disease model, wherea

20 cantly protected podocytes against puromycin aminonucleoside-induced injury (designed to mimic nephro

21 ctin cytoskeleton that accompanied puromycin aminonucleoside-induced injury in vitro.

22 reduced peak proteinuria caused by puromycin aminonucleoside-induced nephropathy.

23 Rats with puromycin-aminonucleoside-induced nephrotic proteinuria displayed

24 ritoneum permeability of rats with puromycin aminonucleoside-induced nephrotic syndrome.

25 lpha(3) integrin protected against puromycin aminonucleoside-induced podocyte detachment.

26 We found that puromycin aminonucleoside-induced proteinuria in rats was signific

27 rization of EPZ-5676, a potent and selective aminonucleoside inhibitor of DOT1L histone methyltransfe

28 y increased GEN sprouting, whereas puromycin aminonucleoside-injured podocyte supernatant decreased t

29 Notably, in the puromycin aminonucleoside model, hyperfibrinogenemia and antithrom

30 In puromycin aminonucleoside nephrosis (PAN), GIV expression increase

31 ere, we show that the induction of puromycin aminonucleoside nephrosis involves podocyte migration co

32 Furthermore, the rat puromycin aminonucleoside nephrosis model, previously suspected of

33 evels of proteinuria were induced (using the aminonucleoside of puromycin) in normocomplementemic and

34 in humans, in animals treated with puromycin aminonucleoside, or in humans or animals with mutations

35 the passive Heymann nephritis and puromycin aminonucleoside (PA) nephrosis rat models of podocyte in

36 docytes in culture were exposed to puromycin aminonucleoside (PA) to induce apoptosis.

37 type C57Bl/6 mice are resistant to puromycin aminonucleoside (PA)-induced nephrosis (PAN), Podxl(+/-)

38 on and phosphorylation of hsp27 in puromycin aminonucleoside (PAN) -induced experimental NS.

39 n podocytes from rats treated with puromycin aminonucleoside (PAN) and from patients with focal segme

40 a in a rat model of MCD induced by puromycin aminonucleoside (PAN) and in vitro cultured mouse podocy

41 performed comparative studies in a puromycin aminonucleoside (PAN) nephropathy rat model treated with

42 ts of this mutation in response to puromycin aminonucleoside (PAN) nephrosis.

43 and 21 days after the induction of puromycin aminonucleoside (PAN) nephrosis.

44 y rats by intravenous injection of puromycin aminonucleoside (PAN), whereas control rats received phy

45 Here, we compared responses to puromycin aminonucleoside (PAN)-induced kidney injury between INF2

46 function and structure in chronic puromycin aminonucleoside (PAN)-induced nephropathy in rats were e

47 Puromycin aminonucleoside (PAN)-induced nephrosis is a well-descri

48 a glomerular injury-inducing agent puromycin aminonucleoside (PAN).

49 The inactive agent, puromycin aminonucleoside, produced marked repression of the PB-in

50 eraction is disrupted in GECs from puromycin aminonucleoside-, protamine sulfate-, or sialidase-treat

51 foot process effacement using the puromycin aminonucleoside rat model resulted in significant increa

52 The peritoneum of puromycin aminonucleoside rats displayed an increase in the water

53 n of receptor-operated channels in puromycin aminonucleoside-treated podocytes leads to increased cal

54 WT1 heterozygous knockout mice and puromycin aminonucleoside-treated rats).

55 Puromycin aminonucleoside treatment up-regulates cathepsin L expre

56 Puromycin aminonucleoside was without effect on these pathways, de

57 The base-protected alpha-5'-O-DMT-3'-aminonucleosides were assembled into dimers and oligonuc